| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Specific molecular targets of Senkyunolide H are not fully characterized. As a phthalide, it is believed to interact with pathways related to vasodilation, neuroprotection, and anti-inflammation, but its precise receptor or enzyme targets remain under investigation.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that Senkyunolide H possesses antioxidant and neuroprotective activities. It can protect neuronal cells from oxidative stress-induced damage and may modulate inflammatory cytokine production.
|
| ln Vivo |
In vivo, Senkyunolide H has been studied for its potential to improve cerebral blood flow and protect against ischemic brain injury. It may also exert anti-inflammatory effects in animal models of neuroinflammation.
|
| Enzyme Assay |
Receptor binding assays for Senkyunolide H are not well established. Studies typically use cell-based assays to evaluate its neuroprotective or anti-inflammatory effects rather than direct enzyme or receptor binding measurements.
|
| Cell Assay |
Neuronal cell lines such as PC12 or primary cortical neurons are cultured and exposed to oxidative stress inducers (e.g., H2O2 or glutamate) in the presence of Senkyunolide H. Cell viability and markers of oxidative stress are measured.
|
| Animal Protocol |
Ischemic stroke models in rodents, such as middle cerebral artery occlusion (MCAO), are used to evaluate neuroprotective effects. Senkyunolide H is administered orally or intraperitoneally, and infarct volume, neurological scores, and cerebral blood flow are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Senkyunolide H are not extensively studied. As a small lipophilic molecule, it is expected to have good oral absorption and blood-brain barrier penetration, but detailed PK parameters are lacking.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Senkyunolide H are limited. Phthalides are generally considered to have a low toxicity profile. No significant adverse effects have been reported at pharmacological doses.
|
| References | |
| Additional Infomation |
Senkyunolide H is a research compound with no clinical trial or regulatory approval status. It is used primarily as a reference standard and in pharmacological studies of neuroprotection and cerebrovascular diseases.
|
| Molecular Formula |
C12H16O4
|
|---|---|
| Molecular Weight |
224.2530
|
| Exact Mass |
224.104
|
| CAS # |
94596-27-7
|
| PubChem CID |
5316704
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
444.8±45.0 °C at 760 mmHg
|
| Flash Point |
175.1±22.2 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
1.04
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC/C=C\1/C2=C(C(C(CC2)O)O)C(=O)O1
|
| InChi Key |
DQNGMIQSXNGHOA-WTKPLQERSA-N
|
| InChi Code |
InChI=1S/C12H16O4/c1-2-3-4-9-7-5-6-8(13)11(14)10(7)12(15)16-9/h4,8,11,13-14H,2-3,5-6H2,1H3/b9-4-
|
| Chemical Name |
(3Z)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~445.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4593 mL | 22.2965 mL | 44.5931 mL | |
| 5 mM | 0.8919 mL | 4.4593 mL | 8.9186 mL | |
| 10 mM | 0.4459 mL | 2.2297 mL | 4.4593 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
